Moving beyond surrogate endpoints in cell therapy trials for heart disease

Konstantinos Malliaras, Eduardo Marbán

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


Cell therapy for heart disease began clinically more than a decade ago. Since then, numerous trials have been performed, but the studies have been underpowered, focusing primarily on low-risk patients with a recent myocardial infarction. Many data have accumulated on surrogate endpoints such as ejection fraction, but few clinical conclusions can be drawn from such studies. We argue here that the time is right for targeting larger and/or higher-risk populations for whom there is some expectation of being able to influence mortality or rehospitalization.

Original languageEnglish (US)
Pages (from-to)2-6
Number of pages5
JournalStem cells translational medicine
Issue number1
StatePublished - 2014
Externally publishedYes

ASJC Scopus subject areas

  • Cell Biology
  • Developmental Biology


Dive into the research topics of 'Moving beyond surrogate endpoints in cell therapy trials for heart disease'. Together they form a unique fingerprint.

Cite this